Skip to main content
Top
Published in: Diabetologia 6/2013

01-06-2013 | Article

Lysophosphatidic acid impairs glucose homeostasis and inhibits insulin secretion in high-fat diet obese mice

Authors: C. Rancoule, C. Attané, S. Grès, A. Fournel, R. Dusaulcy, C. Bertrand, C. Vinel, K. Tréguer, M. Prentki, P. Valet, J. S. Saulnier-Blache

Published in: Diabetologia | Issue 6/2013

Login to get access

Abstract

Aims/hypothesis

Lysophosphatidic acid (LPA) is a lipid mediator produced by adipocytes that acts via specific G-protein-coupled receptors; its synthesis is modulated in obesity. We previously reported that reducing adipocyte LPA production in high-fat diet (HFD)-fed obese mice is associated with improved glucose tolerance, suggesting a negative impact of LPA on glucose homeostasis. Here, our aim was to test this hypothesis.

Methods

First, glucose tolerance and plasma insulin were assessed after acute (30 min) injection of LPA (50 mg/kg) or of the LPA1/LPA3 receptor antagonist Ki16425 (5 mg kg−1 day−1, i.p.) in non-obese mice fed a normal diet (ND) and in obese/prediabetic (defined as glucose-intolerant) HFD mice. Glucose and insulin tolerance, pancreas morphology, glycogen storage, glucose oxidation and glucose transport were then studied after chronic treatment (3 weeks) of HFD mice with Ki16425.

Results

In ND and HFD mice, LPA acutely impaired glucose tolerance by inhibiting glucose-induced insulin secretion. These effects were blocked by pre-injection of Ki16425 (5 mg/kg, i.p.). Inhibition of glucose-induced insulin secretion by LPA also occurred in isolated mouse islets. Plasma LPA was higher in HFD mice than in ND mice and Ki16425 transiently improved glucose tolerance. The beneficial effect of Ki16425 became permanent after chronic treatment and was associated with increased pancreatic islet mass and higher fasting insulinaemia. Chronic treatment with Ki16425 also improved insulin tolerance and increased liver glycogen storage and basal glucose use in skeletal muscle.

Conclusions/interpretation

Exogenous and endogenous LPA exerts a deleterious effect on glucose disposal through a reduction of plasma insulin; pharmacological blockade of LPA receptors improves glucose homeostasis in obese/prediabetic mice.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lee MJ, Wu Y, Fried SK (2010) Adipose tissue remodeling in pathophysiology of obesity. Curr Opin Clin Nutr Metab Care 13:371–376PubMedCrossRef Lee MJ, Wu Y, Fried SK (2010) Adipose tissue remodeling in pathophysiology of obesity. Curr Opin Clin Nutr Metab Care 13:371–376PubMedCrossRef
2.
go back to reference Gutierrez DA, Puglisi MJ, Hasty AH (2009) Impact of increased adipose tissue mass on inflammation, insulin resistance, and dyslipidemia. Curr Diabetes Rep 9:26–32CrossRef Gutierrez DA, Puglisi MJ, Hasty AH (2009) Impact of increased adipose tissue mass on inflammation, insulin resistance, and dyslipidemia. Curr Diabetes Rep 9:26–32CrossRef
3.
go back to reference Karastergiou K, Mohamed-Ali V (2010) The autocrine and paracrine roles of adipokines. Mol Cell Endocrinol 318:69–78PubMedCrossRef Karastergiou K, Mohamed-Ali V (2010) The autocrine and paracrine roles of adipokines. Mol Cell Endocrinol 318:69–78PubMedCrossRef
4.
go back to reference Choi JW, Herr DR, Noguchi K et al (2010) LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 50:157–186PubMedCrossRef Choi JW, Herr DR, Noguchi K et al (2010) LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 50:157–186PubMedCrossRef
6.
go back to reference Nakanaga K, Hama K, Aoki J (2010) Autotaxin – an LPA producing enzyme with diverse functions. J Biochem 148:13–24PubMedCrossRef Nakanaga K, Hama K, Aoki J (2010) Autotaxin – an LPA producing enzyme with diverse functions. J Biochem 148:13–24PubMedCrossRef
7.
go back to reference Kano K, Arima N, Ohgami M, Aoki J (2008) LPA and its analogs – attractive tools for elucidation of LPA biology and drug development. Curr Med Chem 15:2122–2131PubMedCrossRef Kano K, Arima N, Ohgami M, Aoki J (2008) LPA and its analogs – attractive tools for elucidation of LPA biology and drug development. Curr Med Chem 15:2122–2131PubMedCrossRef
8.
go back to reference Im DS (2010) Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors. Acta Pharmacol Sin 31:1213–1222PubMedCrossRef Im DS (2010) Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors. Acta Pharmacol Sin 31:1213–1222PubMedCrossRef
9.
go back to reference Rancoule C, Pradere JP, Gonzalez J et al (2011) Lysophosphatidic acid-1-receptor targeting agents for fibrosis. Expert Opin Investig Drugs 20:657–667PubMedCrossRef Rancoule C, Pradere JP, Gonzalez J et al (2011) Lysophosphatidic acid-1-receptor targeting agents for fibrosis. Expert Opin Investig Drugs 20:657–667PubMedCrossRef
10.
go back to reference Ohta H, Sato K, Murata N et al (2003) Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol 64:994–1005PubMedCrossRef Ohta H, Sato K, Murata N et al (2003) Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol 64:994–1005PubMedCrossRef
11.
go back to reference Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clezardin P, Peyruchaud O (2006) The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci U S A 103:9643–9648PubMedCrossRef Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clezardin P, Peyruchaud O (2006) The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci U S A 103:9643–9648PubMedCrossRef
12.
go back to reference Pradere JP, Klein J, Gres S et al (2007) LPA1 receptor activation promotes renal interstitial fibrosis. J Am Soc Nephrol 18:3110–3118PubMedCrossRef Pradere JP, Klein J, Gres S et al (2007) LPA1 receptor activation promotes renal interstitial fibrosis. J Am Soc Nephrol 18:3110–3118PubMedCrossRef
13.
go back to reference Zhou Z, Subramanian P, Sevilmis G et al (2011) Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium. Cell Metab 13:592–600PubMedCrossRef Zhou Z, Subramanian P, Sevilmis G et al (2011) Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium. Cell Metab 13:592–600PubMedCrossRef
14.
go back to reference Valet P, Pages C, Jeanneton O et al (1998) Alpha2-adrenergic receptor-mediated release of lysophosphatidic acid by adipocytes. A paracrine signal for preadipocyte growth. J Clin Invest 101:1431–1438PubMedCrossRef Valet P, Pages C, Jeanneton O et al (1998) Alpha2-adrenergic receptor-mediated release of lysophosphatidic acid by adipocytes. A paracrine signal for preadipocyte growth. J Clin Invest 101:1431–1438PubMedCrossRef
15.
go back to reference Gesta S, Simon MF, Rey A et al (2002) Secretion of a lysophospholipase D activity by adipocytes: involvement in lysophosphatidic acid synthesis. J Lipid Res 43:904–910PubMed Gesta S, Simon MF, Rey A et al (2002) Secretion of a lysophospholipase D activity by adipocytes: involvement in lysophosphatidic acid synthesis. J Lipid Res 43:904–910PubMed
16.
go back to reference Ferry G, Tellier E, Try A et al (2003) Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity. J Biol Chem 278:18162–18169PubMedCrossRef Ferry G, Tellier E, Try A et al (2003) Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity. J Biol Chem 278:18162–18169PubMedCrossRef
17.
go back to reference Boucher J, Quilliot D, Praderes JP et al (2005) Potential involvement of adipocyte insulin resistance in obesity-associated up-regulation of adipocyte lysophospholipase D/autotaxin expression. Diabetologia 48:569–577PubMedCrossRef Boucher J, Quilliot D, Praderes JP et al (2005) Potential involvement of adipocyte insulin resistance in obesity-associated up-regulation of adipocyte lysophospholipase D/autotaxin expression. Diabetologia 48:569–577PubMedCrossRef
18.
go back to reference Rancoule C, Dusaulcy R, Treguer K et al (2012) Depot-specific regulation of autotaxin with obesity in human adipose tissue. J Physiol Biochem 68:635–644PubMedCrossRef Rancoule C, Dusaulcy R, Treguer K et al (2012) Depot-specific regulation of autotaxin with obesity in human adipose tissue. J Physiol Biochem 68:635–644PubMedCrossRef
19.
go back to reference Dusaulcy R, Rancoule C, Gres S et al (2011) Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid. J Lipid Res 52:1247–1255PubMedCrossRef Dusaulcy R, Rancoule C, Gres S et al (2011) Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid. J Lipid Res 52:1247–1255PubMedCrossRef
20.
go back to reference Simon MF, Daviaud D, Pradere JP et al (2005) Lysophosphatidic acid inhibits adipocyte differentiation via lysophosphatidic acid 1 receptor-dependent down-regulation of peroxisome proliferator-activated receptor gamma2. J Biol Chem 280:14656–14662PubMedCrossRef Simon MF, Daviaud D, Pradere JP et al (2005) Lysophosphatidic acid inhibits adipocyte differentiation via lysophosphatidic acid 1 receptor-dependent down-regulation of peroxisome proliferator-activated receptor gamma2. J Biol Chem 280:14656–14662PubMedCrossRef
21.
go back to reference Coy PE, Taneja N, Lee I, Hecquet C, Bryson JM, Robey RB (2002) LPA is a novel lipid regulator of mesangial cell hexokinase activity and HKII isoform expression. Am J Physiol Ren Physiol 283:F271–F279 Coy PE, Taneja N, Lee I, Hecquet C, Bryson JM, Robey RB (2002) LPA is a novel lipid regulator of mesangial cell hexokinase activity and HKII isoform expression. Am J Physiol Ren Physiol 283:F271–F279
22.
go back to reference Keller JN, Steiner MR, Mattson MP, Steiner SM (1996) Lysophosphatidic acid decreases glutamate and glucose uptake by astrocytes. J Neurochem 67:2300–2305PubMedCrossRef Keller JN, Steiner MR, Mattson MP, Steiner SM (1996) Lysophosphatidic acid decreases glutamate and glucose uptake by astrocytes. J Neurochem 67:2300–2305PubMedCrossRef
23.
go back to reference Yea K, Kim J, Lim S et al (2008) Lysophosphatidic acid regulates blood glucose by stimulating myotube and adipocyte glucose uptake. J Mol Med 86:211–220PubMedCrossRef Yea K, Kim J, Lim S et al (2008) Lysophosphatidic acid regulates blood glucose by stimulating myotube and adipocyte glucose uptake. J Mol Med 86:211–220PubMedCrossRef
24.
go back to reference Fan H, Zingarelli B, Harris V, Tempel GE, Halushka PV, Cook JA (2008) Lysophosphatidic acid inhibits bacterial endotoxin-induced pro-inflammatory response: potential anti-inflammatory signaling pathways. Mol Med 14:422–428PubMedCrossRef Fan H, Zingarelli B, Harris V, Tempel GE, Halushka PV, Cook JA (2008) Lysophosphatidic acid inhibits bacterial endotoxin-induced pro-inflammatory response: potential anti-inflammatory signaling pathways. Mol Med 14:422–428PubMedCrossRef
25.
go back to reference Hashimoto T, Ohata H, Momose K (2004) Itch–scratch responses induced by lysophosphatidic acid in mice. Pharmacology 72:51–56PubMedCrossRef Hashimoto T, Ohata H, Momose K (2004) Itch–scratch responses induced by lysophosphatidic acid in mice. Pharmacology 72:51–56PubMedCrossRef
26.
go back to reference Subramanian P, Karshovska E, Reinhard P et al (2010) Lysophosphatidic acid receptors LPA1 and LPA3 promote CXCL12-mediated smooth muscle progenitor cell recruitment in neointima formation. Circ Res 107:96–105PubMedCrossRef Subramanian P, Karshovska E, Reinhard P et al (2010) Lysophosphatidic acid receptors LPA1 and LPA3 promote CXCL12-mediated smooth muscle progenitor cell recruitment in neointima formation. Circ Res 107:96–105PubMedCrossRef
27.
go back to reference Saulnier-Blache JS, Girard A, Simon MF, Lafontan M, Valet P (2000) A simple and highly sensitive radioenzymatic assay for lysophosphatidic acid quantification. J Lipid Res 41:1947–1951PubMed Saulnier-Blache JS, Girard A, Simon MF, Lafontan M, Valet P (2000) A simple and highly sensitive radioenzymatic assay for lysophosphatidic acid quantification. J Lipid Res 41:1947–1951PubMed
28.
go back to reference Nahle Z, Hsieh M, Pietka T et al (2008) CD36-dependent regulation of muscle FoxO1 and PDK4 in the PPAR delta/beta-mediated adaptation to metabolic stress. J Biol Chem 283:14317–14326PubMedCrossRef Nahle Z, Hsieh M, Pietka T et al (2008) CD36-dependent regulation of muscle FoxO1 and PDK4 in the PPAR delta/beta-mediated adaptation to metabolic stress. J Biol Chem 283:14317–14326PubMedCrossRef
29.
go back to reference Dray C, Knauf C, Daviaud D et al (2008) Apelin stimulates glucose utilization in normal and obese insulin-resistant mice. Cell Metab 8:437–445PubMedCrossRef Dray C, Knauf C, Daviaud D et al (2008) Apelin stimulates glucose utilization in normal and obese insulin-resistant mice. Cell Metab 8:437–445PubMedCrossRef
30.
go back to reference Peyot ML, Guay C, Latour MG et al (2009) Adipose triglyceride lipase is implicated in fuel- and non-fuel-stimulated insulin secretion. J Biol Chem 284:16848–16859PubMedCrossRef Peyot ML, Guay C, Latour MG et al (2009) Adipose triglyceride lipase is implicated in fuel- and non-fuel-stimulated insulin secretion. J Biol Chem 284:16848–16859PubMedCrossRef
31.
go back to reference Metz SA (1986) Lysophosphatidylinositol, but not lysophosphatidic acid, stimulates insulin release. A possible role for phospholipase A2 but not de novo synthesis of lysophospholipid in pancreatic islet function. Biochem Biophys Res Commun 138:720–727PubMedCrossRef Metz SA (1986) Lysophosphatidylinositol, but not lysophosphatidic acid, stimulates insulin release. A possible role for phospholipase A2 but not de novo synthesis of lysophospholipid in pancreatic islet function. Biochem Biophys Res Commun 138:720–727PubMedCrossRef
32.
go back to reference Hama K, Bandoh K, Kakehi Y, Aoki J, Arai H (2002) Lysophosphatidic acid (LPA) receptors are activated differentially by biological fluids: possible role of LPA-binding proteins in activation of LPA receptors. FEBS Lett 523:187–192PubMedCrossRef Hama K, Bandoh K, Kakehi Y, Aoki J, Arai H (2002) Lysophosphatidic acid (LPA) receptors are activated differentially by biological fluids: possible role of LPA-binding proteins in activation of LPA receptors. FEBS Lett 523:187–192PubMedCrossRef
33.
go back to reference Nolan CJ, Damm P, Prentki M (2011) Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 378:169–181PubMedCrossRef Nolan CJ, Damm P, Prentki M (2011) Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 378:169–181PubMedCrossRef
Metadata
Title
Lysophosphatidic acid impairs glucose homeostasis and inhibits insulin secretion in high-fat diet obese mice
Authors
C. Rancoule
C. Attané
S. Grès
A. Fournel
R. Dusaulcy
C. Bertrand
C. Vinel
K. Tréguer
M. Prentki
P. Valet
J. S. Saulnier-Blache
Publication date
01-06-2013
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 6/2013
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-013-2891-3

Other articles of this Issue 6/2013

Diabetologia 6/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.